Madrigal Pharmaceuticals (MDGL)

• Market cap: $11.3B
• 1 day: 9.2%
• 5 days: 20.09%
• 1 month: 26.6%
• 3 months: 54.94%
• 6 months: 80.04%
• Year to date: 72.57%
• 1 year: 59.42%
• 5 years: 329.56%
• 10 years: 3,125.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528